ResultsIQ

ResultsIQ › Latest results › Novartis India Limited

Novartis India Limited Q2 FY27 earnings call summary

NSE: NOVARTIND · BSE: 500672

Earnings call of 4 Nov 2026, summarised by AI from the filing.

Evonile Pharma's Q2 FY27 revenue fell to ₹56 cr as the old model ended, with a stabilised base of around ₹600 cr targeted.

Key takeaways

  1. Revenue Q2 FY27 revenue ₹56 cr (Q2 FY26: ₹90 cr), with ₹41 cr of last year's from one major customer.
  2. Risk Costs step up in phases through H2 while revenue is still stabilising, keeping margins under pressure.

Original filing on BSE

Novartis India Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.